GALAPAGOS NV (GLPG.AS) Stock Price & Overview
AMS:GLPG • BE0003818359
The current stock price of GLPG.AS is 28.81 EUR. Today GLPG.AS is up by 2.38%. In the past year, price increased by 17.64%.
GLPG.AS Key Statistics
- Market Cap
- 1.898B
- P/E
- 5.92
- Fwd P/E
- N/A
- EPS (TTM)
- 4.87
- Dividend Yield
- N/A
GLPG.AS Stock Performance
GLPG.AS Stock Chart
GLPG.AS Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to GLPG.AS. When comparing the yearly performance of all stocks, GLPG.AS is one of the better performing stocks in the market, outperforming 72.75% of all stocks.
GLPG.AS Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to GLPG.AS. GLPG.AS is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
GLPG.AS Earnings
On February 24, 2026 GLPG.AS reported an EPS of 11.87 and a revenue of 900.77M. The company beat EPS expectations (329.89% surprise) and beat revenue expectations (977.92% surprise).
GLPG.AS Forecast & Estimates
18 analysts have analysed GLPG.AS and the average price target is 31.14 EUR. This implies a price increase of 8.07% is expected in the next year compared to the current price of 28.81.
For the next year, analysts expect an EPS growth of -150.44% and a revenue growth -0.05% for GLPG.AS
GLPG.AS Groups
Sector & Classification
GLPG.AS Financial Highlights
Over the last trailing twelve months GLPG.AS reported a non-GAAP Earnings per Share(EPS) of 4.87. The EPS increased by 334.82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 28.85% | ||
| ROA | 9.42% | ||
| ROE | 9.92% | ||
| Debt/Equity | 0 |
GLPG.AS Ownership
GLPG.AS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 26.3 | 39.024B | ||
| 1AE | ARGENX SE | 26.1 | 38.999B | ||
| 22UA | BIONTECH SE-ADR | N/A | 20.896B | ||
| ABVX | ABIVAX SA | N/A | 7.504B | ||
| 2X1 | ABIVAX SA | N/A | 7.457B | ||
| GXE | GALAPAGOS NV | N/A | 1.861B | ||
| NANO | NANOBIOTIX | N/A | 1.621B | ||
| 6IV | INVENTIVA SA | N/A | 1.114B | ||
| IVA | INVENTIVA SA | N/A | 1.096B | ||
| PHIL | PHILOGEN SPA | 18.41 | 643.28M | ||
| GNFT | GENFIT | 916.86 | 444.776M | ||
| XUP | GENFIT | N/A | 425.025M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Amsterdam Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About GLPG.AS
Company Profile
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. The company is headquartered in Malines (Mechelen), Antwerpen and currently employs 704 full-time employees. The company went IPO on 2005-05-06. The firm is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The firm focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. The company develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. The company discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The firm acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.
Company Info
IPO: 2005-05-06
GALAPAGOS NV
Generaal De Wittelaan L11 A3
MALINES (MECHELEN) ANTWERPEN BE
Employees: 704
Phone: 3215342900
GALAPAGOS NV / GLPG.AS FAQ
What does GLPG do?
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. The company is headquartered in Malines (Mechelen), Antwerpen and currently employs 704 full-time employees. The company went IPO on 2005-05-06. The firm is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The firm focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. The company develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. The company discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The firm acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.
Can you provide the latest stock price for GALAPAGOS NV?
The current stock price of GLPG.AS is 28.81 EUR. The price increased by 2.38% in the last trading session.
Does GLPG stock pay dividends?
GLPG.AS does not pay a dividend.
What is the ChartMill rating of GALAPAGOS NV stock?
GLPG.AS has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Which stock exchange lists GLPG stock?
GLPG.AS stock is listed on the Euronext Amsterdam exchange.
How is the valuation of GALAPAGOS NV (GLPG.AS) based on its PE ratio?
The PE ratio for GALAPAGOS NV (GLPG.AS) is 5.92. This is based on the reported non-GAAP earnings per share of 4.87 and the current share price of 28.81 EUR.